Pancreatic Cancer: First Patients Treated in RASolute 309 Phase 3
In short: Revolution Medicines announced on October 5, 2026 that it has begun treating patients in RASolute 309, a global Phase 3 trial comparing daraxonrasib plus zoldonrasib with standard chemotherapy as first treatment for metastatic pancreatic cancer with a RAS G12D change. No results exist yet, and the combination is not approved. This is a trial start, not a treatment result.
What was announced
Revolution Medicines said it has begun treating patients in RASolute 309 (NCT07805954), a global, randomized, open-label Phase 3 trial. It enrolls adults with metastatic pancreatic adenocarcinoma that carries the RAS G12D change and who have not been treated before.
How the trial is set up
One group gets daraxonrasib (brand name Rasonque) plus zoldonrasib. The other gets gemcitabine plus nab-paclitaxel, a standard chemotherapy pairing. The main goals are progression-free survival (time without the cancer growing) and overall survival.
Approval status
According to the company, daraxonrasib is FDA-approved for previously treated metastatic pancreatic cancer. Zoldonrasib is still investigational, and the combination as a first treatment is only under study. The company calls RASolute 309 the first Phase 3 study of a RAS(ON) inhibitor doublet.
Why it matters
The company says RAS G12D occurs in about 40% of pancreatic cancers and that five-year survival for metastatic disease is about 3%. A trial start is a step toward an answer, not an answer: no efficacy results from RASolute 309 have been reported, and the announcement is a company release.
Frequently asked questions
Is there a new pancreatic cancer treatment available from this trial?
Not from this trial. The combination is under study and has no results yet. People interested in trials can ask their care team about eligibility.
What is RAS G12D pancreatic cancer?
It is pancreatic cancer whose tumor cells carry a specific change in the RAS gene. Revolution Medicines says about 40% of pancreatic cancers have it.
Read the full Pancreatic cancer report: latest studies, treatments, trials near you, expert care centers and support groups, updated daily.
Sources
- Revolution Medicines begins treating patients in Phase 3 RASolute 309 trial. Revolution Medicines via GlobeNewswire, October 5, 2026
More from the newsroom
- Alzheimer's: Largest Gene Study Finds 48 New Risk Regions (October 30, 2026)
- Cystic Fibrosis: Home Monitoring Trial Misses Main Goal (October 30, 2026)
- Crohn's Disease: Skyrizi Injected Starter Doses in AFFIRM Phase 3 (October 23, 2026)